Larry A Allen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11500121/publications.pdf

Version: 2024-02-01

		22146	15265
193	17,534	59	126
papers	citations	h-index	g-index
196	196	196	17625
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Forecasting the Impact of Heart Failure in the United States. Circulation: Heart Failure, 2013, 6, 606-619.	3.9	2,206
2	Frailty Assessment in the Cardiovascular Care of Older Adults. Journal of the American College of Cardiology, 2014, 63, 747-762.	2.8	850
3	Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. Journal of the American College of Cardiology, 2007, 50, 40-47.	2.8	809
4	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	2.8	774
5	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR0000000000001063.	1.6	756
6	Decision Making in Advanced Heart Failure. Circulation, 2012, 125, 1928-1952.	1.6	678
7	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 772-810.	2.8	612
8	Hospital Readmissions Reduction Program. Circulation, 2015, 131, 1796-1803.	1.6	475
9	Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study. Journal of the National Cancer Institute, 2012, 104, 1293-1305.	6.3	469
10	Health Literacy and Outcomes Among Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2011, 305, 1695.	7.4	347
11	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. JAMA Cardiology, 2018, 3, 44.	6.1	346
12	Validation and Potential Mechanisms of Red Cell Distribution Width as a Prognostic Marker in Heart Failure. Journal of Cardiac Failure, 2010, 16, 230-238.	1.7	344
13	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation, 2019, 140, e294-e324.	1.6	342
14	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure, 2009, 11, 170-177.	7.1	326
15	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 1757-1780.	2.8	314
16	Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure, 2015, 21, 519-534.	1.7	283
17	Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association. Circulation, 2018, 137, e623-e644.	1.6	279
18	2017 ACC Expert Consensus Decision Pathway for Optimization of HeartÂFailure Treatment: Answers to 10ÂPivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2018, 71, 201-230.	2.8	235

#	Article	IF	Citations
19	Discordance Between Patient-Predicted and Model-Predicted Life Expectancy Among Ambulatory Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2008, 299, 2533.	7.4	233
20	Impact of Medication Nonadherence on Hospitalizations and Mortality in Heart Failure. Journal of Cardiac Failure, 2011, 17, 664-669.	1.7	210
21	Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2015, 169, 647-654.e2.	2.7	202
22	Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men. JAMA Cardiology, 2016, 1, 282.	6.1	182
23	Discharge to a Skilled Nursing Facility and Subsequent Clinical Outcomes Among Older Patients Hospitalized for Heart Failure. Circulation: Heart Failure, 2011, 4, 293-300.	3.9	165
24	Frailty and the Selection of Patients for Destination Therapy Left Ventricular Assist Device. Circulation: Heart Failure, 2012, 5, 286-293.	3.9	142
25	Clinical Outcomes After Continuous-Flow Left Ventricular Assist Device. Circulation: Heart Failure, 2014, 7, 1003-1013.	3.9	140
26	Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. American Heart Journal, 2014, 167, 601-609.e1.	2.7	135
27	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR000000000001062.	1.6	133
28	Effectiveness of an Intervention Supporting Shared Decision Making for Destination Therapy Left Ventricular Assist Device. JAMA Internal Medicine, 2018, 178, 520.	5.1	132
29	Palliative care in patients with heart failure. BMJ, The, 2016, 353, i1010.	6.0	124
30	Effect of a Collaborative Care Intervention vs Usual Care on Health Status of Patients With Chronic Heart Failure. JAMA Internal Medicine, 2018, 178, 511.	5.1	123
31	Effects of Oxygen Concentration on the Expression of Cytochrome c and Cytochrome c Oxidase Genes in Yeast. Journal of Biological Chemistry, 1997, 272, 14705-14712.	3.4	119
32	Identifying Patients Hospitalized With Heart Failure at Risk for Unfavorable Future Quality of Life. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 389-398.	2,2	111
33	Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death. Circulation, 2016, 133, 1715-1727.	1.6	108
34	Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2014, 168, 487-494.	2.7	107
35	Aging of the United States Population: Impact on Heart Failure. Current Heart Failure Reports, 2012, 9, 369-374.	3.3	94
36	Patient-Identified Factors Related to Heart Failure Readmissions. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 171-177.	2.2	94

#	Article	IF	CITATIONS
37	Cardiac Calcitropes, Myotropes, andÂMitotropes. Journal of the American College of Cardiology, 2019, 73, 2345-2353.	2.8	93
38	End Points for Clinical Trials in Acute Heart Failure Syndromes. Journal of the American College of Cardiology, 2009, 53, 2248-2258.	2.8	92
39	Palliative Care and Hospice in Advanced Heart Failure. Progress in Cardiovascular Diseases, 2011, 54, 168-178.	3.1	91
40	Predictors and Prognostic Implications ofÂlncident Heart Failure in Patients WithÂPrevalent Atrial Fibrillation. JACC: Heart Failure, 2017, 5, 44-52.	4.1	91
41	Isoforms of Yeast Cytochrome c Oxidase Subunit V Affect the Binuclear Reaction Center and Alter the Kinetics of Interaction with the Isoforms of Yeast Cytochrome c. Journal of Biological Chemistry, 1995, 270, 110-118.	3.4	89
42	Giving Voice to Patients' and Family Caregivers' Needs in Chronic Heart Failure: Implications for Palliative Care Programs. Journal of Palliative Medicine, 2011, 14, 1317-1324.	1.1	89
43	An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction. Circulation, 2021, 143, 427-437.	1.6	88
44	Contemporary Prevalence and Correlates of Incident Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2013, 126, 393-400.	1.5	82
45	Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. Circulation, 2015, 132, 1347-1353.	1.6	81
46	African Americans Are Less Likely to Receive Care by a Cardiologist During anÂlntensive Care Unit Admission for HeartÂFailure. JACC: Heart Failure, 2018, 6, 413-420.	4.1	81
47	Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. European Journal of Heart Failure, 2019, 21, 1064-1078.	7.1	79
48	Critical elements of clinical followâ€up after hospital discharge for heart failure: insights from the EVEREST trial. European Journal of Heart Failure, 2010, 12, 367-374.	7.1	78
49	Comparison of long-term mortality across the spectrum of acute coronary syndromes. American Heart Journal, 2006, 151, 1065-1071.	2.7	77
50	Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary AtrialÂFibrillation Cohort. Journal of the American College of Cardiology, 2015, 65, 2691-2698.	2.8	76
51	Decision Making for Destination Therapy Left Ventricular Assist Devices. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 374-380.	2.2	74
52	Bereaved Caregiver Perspectives on the End-of-Life Experience of Patients With a Left Ventricular Assist Device. JAMA Internal Medicine, 2016, 176, 534.	5.1	72
53	Management of acute decompensated heart failure. Cmaj, 2007, 176, 797-805.	2.0	71
54	Continuous Versus Bolus Dosing of Furosemide for Patients Hospitalized for Heart Failure. American Journal of Cardiology, 2010, 105, 1794-1797.	1.6	71

#	Article	IF	CITATIONS
55	Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	71
56	Use of Risk Models to Predict Death in the Next Year Among Individual Ambulatory Patients With Heart Failure. JAMA Cardiology, 2017, 2, 435.	6.1	70
57	Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. Journal of Cardiac Failure, 2018, 24, 682-694.	1.7	70
58	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines—Heart Failure. Journal of the American Heart Association, 2019, 8, e011560.	3.7	68
59	Team-based Palliative and End-of-life Care for Heart Failure. Heart Failure Clinics, 2015, 11, 479-498.	2.1	65
60	Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. American Heart Journal, 2019, 211, 77-89.	2.7	64
61	Rates and Predictors of 30-Day Readmission Among Commercially Insured and Medicaid-Enrolled Patients Hospitalized With Systolic Heart Failure. Circulation: Heart Failure, 2012, 5, 672-679.	3.9	62
62	Patient factors associated with quality of life in atrial fibrillation. American Heart Journal, 2016, 182, 135-143.	2.7	62
63	The Affordable Care Act Medicaid Expansion Correlated With Increased Heart Transplant Listings in African-Americans But Not Hispanics orÂCaucasians. JACC: Heart Failure, 2017, 5, 136-147.	4.1	61
64	Natural History of Left Ventricular Ejection Fraction in Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 680-686.	2.2	59
65	Ambulatory Inotrope Infusions in Advanced Heart Failure. JACC: Heart Failure, 2018, 6, 757-767.	4.1	59
66	Outpatient Palliative Care for Chronic Heart Failure: A Case Series. Journal of Palliative Medicine, 2011, 14, 815-821.	1.1	58
67	Temporal Trends in Contemporary Use of Ventricular Assist Devices by Race and Ethnicity. Circulation: Heart Failure, 2018, 11, e005008.	3.9	58
68	Development of a Decision Aid for PatientsÂWith Advanced Heart Failure Considering a Destination Therapy LeftÂVentricular Assist Device. JACC: Heart Failure, 2015, 3, 965-976.	4.1	57
69	The Hospital Readmissions Reduction Program. JACC: Heart Failure, 2020, 8, 1-11.	4.1	57
70	High Mortality Without ESCAPE: The Registry of Heart Failure Patients Receiving Pulmonary Artery Catheters Without Randomization. Journal of Cardiac Failure, 2008, 14, 661-669.	1.7	56
71	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. Journal of Cardiac Failure, 2019, 25, 584-619.	1.7	56
72	A Multicenter Trial of a Shared Decision Support Intervention for Patients and Their Caregivers Offered Destination Therapy for Advanced Heart Failure: DECIDE-LVAD. Journal of Cardiovascular Nursing, 2016, 31, E8-E20.	1.1	54

#	Article	IF	CITATIONS
73	Frequency of Poor Outcome (Death or Poor Quality of Life) After Left Ventricular Assist Device for Destination Therapy. Circulation: Heart Failure, 2016, 9, .	3.9	54
74	How Medicine Has Changed the End of Life for Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2017, 70, 1276-1289.	2.8	52
75	Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelines–Heart Failure Registry. JAMA Cardiology, 2018, 3, 917.	6.1	50
76	Deactivation of Left Ventricular Assist Devices: Differing Perspectives of Cardiology and Hospice/Palliative Medicine Clinicians. Journal of Cardiac Failure, 2017, 23, 708-712.	1.7	49
77	Postdischarge Environment Following Heart Failure Hospitalization: Expanding the View of Hospital Readmission. Journal of the American Heart Association, 2013, 2, e000116.	3.7	47
78	[8] Cytochrome-c oxidase from Saccharomyces cerevisiae. Methods in Enzymology, 1995, 260, 97-116.	1.0	45
79	The Perceptions of Important Elements of Caregiving for a Left Ventricular Assist Device Patient. Journal of Cardiovascular Nursing, 2016, 31, 215-225.	1.1	45
80	Psychosocial Evaluation of Candidates for Heart Transplant and Ventricular Assist Devices: Beyond the Current Consensus. Circulation: Heart Failure, 2019, 12, e006058.	3.9	45
81	Improvements in Signs and Symptoms During Hospitalization for Acute Heart Failure Follow Different Patterns and Depend on the Measurement Scales Used: An International, Prospective Registry to Evaluate the Evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF). Journal of Cardiac Failure, 2008, 14, 777-784.	1.7	43
82	Decision-Making for Destination Therapy Left Ventricular Assist Devices. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 172-178.	2.2	42
83	2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of Cardiac Failure, 2022, 28, 810-830.	1.7	42
84	Accuracy of physician prognosis in heart failure and lung cancer: Comparison between physician estimates and model predicted survival. Palliative Medicine, 2016, 30, 684-689.	3.1	41
85	Care concordant with guidelines predicts decreased long-term mortality in patients with unstable angina pectoris and non–ST-Elevation myocardial infarction. American Journal of Cardiology, 2004, 93, 1218-1222.	1.6	40
86	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. Journal of Cardiac Failure, 2015, 21, 674-693.	1.7	39
87	Referral Criteria to Palliative Care for Patients With Heart Failure. Circulation: Heart Failure, 2020, 13, e006881.	3.9	38
88	Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Tj ETQq0 0 0 rgB1	/Owerloc	k 1 97 f 50 137
89	Discussing Outâ€ofâ€Pocket Costs With Patients: Shared Decision Making for Sacubitrilâ€Valsartan in Heart Failure. Journal of the American Heart Association, 2019, 8, e010635.	3.7	37
90	Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation. American Journal of Medicine, 2013, 126, 625-632.e1.	1.5	34

#	Article	IF	Citations
91	Educational Resources for Patients Considering a Left Ventricular Assist Device. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 905-911.	2.2	33
92	Assessing Frailty in Patients Undergoing Destination Therapy Left Ventricular Assist Device: Observations from Interagency Registry for Mechanically Assisted Circulatory Support. ASAIO Journal, 2018, 64, 16-23.	1.6	33
93	Drug Layering in HeartÂFailure. JACC: Heart Failure, 2021, 9, 775-783.	4.1	32
94	Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non–ST-elevation myocardial infarction. American Journal of Cardiology, 2003, 92, 1155-1159.	1.6	31
95	Risk Factors for Adverse Outcomes by Left Ventricular Ejection Fraction in a Contemporary Heart Failure Population. Circulation: Heart Failure, 2013, 6, 635-646.	3.9	31
96	Acculturation and Outcomes Among Patients With Heart Failure. Circulation: Heart Failure, 2012, 5, 160-166.	3.9	30
97	The inpatient experience and predictors of length of stay for patients hospitalized with systolic heart failure: comparison by commercial, Medicaid, and Medicare payer type. Journal of Medical Economics, 2013, 16, 43-54.	2.1	30
98	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2021, 27, 826-836.	1.7	30
99	Multi-marker strategies in heart failure: clinical and statistical approaches. Heart Failure Reviews, 2010, 15, 343-349.	3.9	28
100	Hospital Variation in Intravenous Inotrope Use for Patients Hospitalized With Heart Failure. Circulation: Heart Failure, 2014, 7, 251-260.	3.9	28
101	Caregivers of Patients Considering a Destination Therapy Left Ventricular Assist Device and a Shared Decision-Making Intervention. JACC: Heart Failure, 2018, 6, 904-913.	4.1	28
102	Bâ€Type Natriuretic Peptide Predicts 30â€Day Readmission for Heart Failure but not Readmission for Other Causes. Journal of the American Heart Association, 2014, 3, e000806.	3.7	27
103	End of life for patients with left ventricular assist devices: Insights from INTERMACS. Journal of Heart and Lung Transplantation, 2019, 38, 374-381.	0.6	27
104	Performance of Claims-based Algorithms for Identifying Heart Failure and Cardiomyopathy Among Patients Diagnosed With Breast Cancer. Medical Care, 2014, 52, e30-e38.	2.4	25
105	Patient-Reported Outcomes in Heart Failure: Existing Measures and Future Uses. Current Heart Failure Reports, 2015, 12, 236-246.	3.3	24
106	Evidence of Cognitive Bias in Decision Making Around Implantable-Cardioverter Defibrillators: A Qualitative Framework Analysis. Journal of Cardiac Failure, 2017, 23, 794-799.	1.7	24
107	Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation, 2018, 138, 889-897.	1.6	23
108	Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart, 2018, 104, 1850-1858.	2.9	23

#	Article	IF	CITATIONS
109	Rationale and study design of a patient-centered intervention to improve health status in chronic heart failure: The Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) randomized trial. Contemporary Clinical Trials, 2016, 51, 1-7.	1.8	22
110	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart, 2019, 105, heartjnl-2018-313642.	2.9	22
111	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. American Heart Journal, 2020, 220, 41-50.	2.7	22
112	Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) – Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure. Journal of Cardiac Failure, 2022, 28, 1245-1254.	1.7	22
113	Criteria for Referral of Patients With Advanced HeartÂFailure for Specialized Palliative Care. Journal of the American College of Cardiology, 2022, 80, 332-344.	2.8	22
114	Advances in the surgical treatment of heart failure. Current Opinion in Cardiology, 2008, 23, 249-253.	1.8	20
115	Perspectives from mechanical circulatory support coordinators on the pre-implantation decision process for destination therapy left ventricular assist devices. Heart and Lung: Journal of Acute and Critical Care, 2015, 44, 219-224.	1.6	20
116	Thinking Outside the Box: Treating Acute Heart Failure Outside the Hospital to Improve Care and Reduce Admissions. Journal of Cardiac Failure, 2015, 21, 667-673.	1.7	20
117	Health Status Trajectories Among Outpatients With HeartÂFailure. Journal of Pain and Symptom Management, 2017, 53, 224-231.	1.2	20
118	Palliative Inotrope Therapy. JAMA Cardiology, 2019, 4, 815.	6.1	20
119	Skilled Nursing Facility Care for Patients With Heart Failure: Can We Make It "Heart Failure Ready?―		
	Journal of Cardiac Failure, 2016, 22, 1004-1014.	1.7	19
120	End Points for Comparative Effectiveness Research in Heart Failure. Heart Failure Clinics, 2013, 9, 15-28.	2.1	19
120 121			
	End Points for Comparative Effectiveness Research in Heart Failure. Heart Failure Clinics, 2013, 9, 15-28. Patient Perspectives on Communication of Individualized Survival Estimates in Heart Failure. Journal	2.1	18
121	End Points for Comparative Effectiveness Research in Heart Failure. Heart Failure Clinics, 2013, 9, 15-28. Patient Perspectives on Communication of Individualized Survival Estimates in Heart Failure. Journal of Cardiac Failure, 2017, 23, 272-277. Pre-operative health status and outcomes after continuous-flow left ventricular assist device	2.1	18
121 122	End Points for Comparative Effectiveness Research in Heart Failure. Heart Failure Clinics, 2013, 9, 15-28. Patient Perspectives on Communication of Individualized Survival Estimates in Heart Failure. Journal of Cardiac Failure, 2017, 23, 272-277. Pre-operative health status and outcomes after continuous-flow left ventricular assist device implantation. Journal of Heart and Lung Transplantation, 2013, 32, 1249-1254. Relationship Between Anemia and Health Care Costs in Heart Failure. Journal of Cardiac Failure, 2009,	2.1 1.7 0.6	18 18 17
121 122 123	End Points for Comparative Effectiveness Research in Heart Failure. Heart Failure Clinics, 2013, 9, 15-28. Patient Perspectives on Communication of Individualized Survival Estimates in Heart Failure. Journal of Cardiac Failure, 2017, 23, 272-277. Pre-operative health status and outcomes after continuous-flow left ventricular assist device implantation. Journal of Heart and Lung Transplantation, 2013, 32, 1249-1254. Relationship Between Anemia and Health Care Costs in Heart Failure. Journal of Cardiac Failure, 2009, 15, 843-849.	2.1 1.7 0.6	18 18 17

#	Article	IF	Citations
127	The Complex Relationship of Race to Outcomes in Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2015, 128, 591-600.	1.5	14
128	Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006255.	2.2	14
129	Defibrillators, Deactivation, Decisions, and Dying. JAMA Internal Medicine, 2013, 173, 379.	5.1	13
130	Timing of Postdischarge Followâ€Up and Medication Adherence Among Patients With Heart Failure. Journal of the American Heart Association, 2018, 7, .	3.7	13
131	Applying Clinical Decision Support Design Best Practices With the Practical Robust Implementation and Sustainability Model Versus Reliance on Commercially Available Clinical Decision Support Tools: Randomized Controlled Trial. JMIR Medical Informatics, 2021, 9, e24359.	2.6	13
132	Signs, symptoms, and treatment patterns across serial ambulatory cardiology visits in patients with heart failure: insights from the NCDR PINNACLE® registry. BMC Cardiovascular Disorders, 2018, 18, 80.	1.7	12
133	Use of Multiple Biomarkers in Heart Failure. Current Cardiology Reports, 2010, 12, 230-236.	2.9	11
134	Patterns of beta-blocker intensification in ambulatory heart failure patients and short-term association with hospitalization. BMC Cardiovascular Disorders, 2012, 12, 43.	1.7	10
135	Decision Aid Implementation among Left Ventricular Assist Device Programs Participating in the DECIDE-LVAD Stepped-Wedge Trial. Medical Decision Making, 2020, 40, 289-301.	2.4	10
136	Primary palliative care for heart failure provided within ambulatory cardiology: A randomized pilot trial. Heart and Lung: Journal of Acute and Critical Care, 2022, 56, 125-132.	1.6	10
137	Can We Predict Who Will Be Alive and Well After Transcatheter Aortic Valve Replacement? Is That Useful to Individual Patients?. Circulation, 2014, 129, 2636-2637.	1.6	8
138	Exploring cognitive bias in destination therapy left ventricular assist device decision making: A retrospective qualitative framework analysis. American Heart Journal, 2016, 180, 64-73.	2.7	8
139	Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease. Journal of the American Geriatrics Society, 2017, 65, 2610-2618.	2.6	8
140	The American Heart Association Heart Failure Summit, Bethesda, April 12, 2017. Circulation: Heart Failure, 2018, 11, e004957.	3.9	8
141	Patient Roadmaps for Chronic Illness: Introducing a New Approach for Fostering Patient-Centered Care. MDM Policy and Practice, 2021, 6, 238146832110199.	0.9	8
142	Development and piloting of four decision aids for implantable cardioverterâ€defibrillators in different media formats. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 1842-1852.	1.2	8
143	The evolving landscape of quality measurement for heart failure. Annals of the New York Academy of Sciences, 2012, 1254, 131-139.	3.8	7
144	Outcomes in Acute Heart Failure: 30-Day Readmission Versus Death. Current Heart Failure Reports, 2014, 11, 445-452.	3.3	7

#	Article	IF	Citations
145	The influence of expected risks on decision making for destination therapy left ventricular assist device: An MTurk survey. Journal of Heart and Lung Transplantation, 2015, 34, 988-990.	0.6	7
146	Association of global and disease-specific health status with outcomes following continuous-flow left ventricular assist device implantation. BMC Cardiovascular Disorders, 2017, 17, 78.	1.7	7
147	Left Ventricular Assist Device Withdrawal: Ethical, Psychological, and Logistical Challenges. Journal of Palliative Medicine, 2020, 23, 456-458.	1.1	7
148	A multicenter trial of a shared DECision Support Intervention for Patients offered implantable Cardioverter-DEfibrillators: DECIDE-ICD rationale, design, Medicare changes, and pilot data. American Heart Journal, 2020, 226, 161-173.	2.7	7
149	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008594.	3.9	7
150	How Should Physicians Respond to Requests for LVAD Removal?. AMA Journal of Ethics, 2019, 21, E394-400.	0.7	6
151	Social Determinants of Health and Rates of Implantation for Patients Considering Destination Therapy Left Ventricular Assist Device. Journal of Cardiac Failure, 2021, 27, 497-500.	1.7	6
152	To DT or Not to DT, That Is the Question. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 13-14.	2.2	5
153	Anchoring in Destination-Therapy Left Ventricular Assist Device Decision Making: A Mechanical Turk Survey. Journal of Cardiac Failure, 2016, 22, 908-912.	1.7	5
154	Organic Dissemination and Real-World Implementation of Patient Decision Aids for Left Ventricular Assist Device. MDM Policy and Practice, 2018, 3, 238146831876765.	0.9	5
155	An Electronically delivered, Patient-activation tool for Intensification of medications for Chronic Heart Failure with reduced ejection fraction: Rationale and design of the EPIC-HF trial. American Heart Journal, 2020, 229, 144-155.	2.7	5
156	Systematizing Heart Failure Population Health. Heart Failure Clinics, 2020, 16, 457-466.	2.1	5
157	Perceived Stress and Depressive Symptoms as Predictors of Decisional Conflict in Dyads Considering a Left Ventricular Assist Device. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006155.	2.2	5
158	Use of Outpatient Intravenous Calcitropes for Heart Failure in the United States. Journal of Cardiac Failure, 2021, 27, 1276-1279.	1.7	5
159	Changes over Time in Patient Stated Values and Treatment Preferences Regarding Aggressive Therapies: Insights from the DECIDE-LVAD Trial. Medical Decision Making, 2022, 42, 404-414.	2.4	5
160	Palliative Care for Patients With Heart Failure: Results From a Heart Failure Society of America Survey. Journal of Cardiac Failure, 2023, 29, 112-115.	1.7	5
161	Managing the Economic Challenges in the Treatment of Heart Failure. Progress in Cardiovascular Diseases, 2018, 61, 476-483.	3.1	4
162	Stress and Coping Among Family Caregivers of Patients With a Destination Therapy Left Ventricular Assist Device: A Multicenter Mixed Methods Study. Circulation: Heart Failure, 2021, 14, e008243.	3.9	4

#	Article	IF	Citations
163	Managing the economic challenges in the treatment of heart failure. BMC Cardiovascular Disorders, 2021, 21, 612.	1.7	4
164	Getting a Grip on Frailty: Handgrip Strength in Patient Selection for Left Ventricular Assist Device. Journal of Cardiac Failure, 2014, 20, 316-318.	1.7	3
165	Metaâ€Analysis of Medication Adherence Interventions Among Heart Failure Patients: The Lumpers Make Their Case. Journal of the American Heart Association, 2016, 5, .	3.7	3
166	Shared Decision-Making for Left Ventricular Assist Devices. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007256.	2.2	3
167	Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation: Heart Failure, 2021, 14, e007759.	3.9	3
168	Profile of Patients Hospitalized for Heart Failure Who Leave Against Medical Advice. Journal of Cardiac Failure, 2021, 27, 747-755.	1.7	3
169	Behind the Scenes in "The Real World―ofÂHeart Transplantation. Journal of the American College of Cardiology, 2018, 71, 1726-1728.	2.8	2
170	When the VEST Does Not Fit. Circulation: Heart Failure, 2018, 11, e005116.	3.9	2
171	When a Shortâ€Term Outlook Is the Best Longâ€Term Strategy: Timeâ€Varying Risk of Readmission After Acute Myocardial Infarction. Journal of the American Heart Association, 2018, 7, e010864.	3.7	2
172	Development of a Decision Aid for Patients and Families Considering Hospice. Journal of Palliative Medicine, 2021, 24, 505-513.	1.1	2
173	Abstract 92: Approaches to Decision Support and Preparation for Destination Therapy Left Ventricular Assist Device: A Nationwide Sample of Mechanical Circulatory Support Coordinators. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, .	2.2	2
174	Quality of Life After Left Ventricular Assist Device Implantation: In a World Full of Data, #Missingness. Journal of Cardiac Failure, 2016, 22, 338-339.	1.7	1
175	Educate, Engage, Empower. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e006107.	2.2	1
176	Exploring differences between patients who accept, decline, and are deemed ineligible for left ventricular assist device implantation as destination therapy. Journal of Heart and Lung Transplantation, 2020, 39, 721-724.	0.6	1
177	Development of a measure of decision quality for implantable defibrillators. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 677-684.	1.2	1
178	Acute Myocardial Infarction Cohorts Defined by International Classification of Diseases, Tenth Revision Versus Diagnosis-Related Groups. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006570.	2.2	1
179	Policy and Payment Challenges in the Postpandemic Treatment of Heart Failure: Value-Based Care and Telehealth. Journal of Cardiac Failure, 2022, 28, 835-844.	1.7	1
180	Psychosocial Considerations of Mechanical Circulatory Support: Decision Making, Behavioral Evaluation, Quality of Life, Caregivers, and End of Life. , 2017, , 467-476.		1

#	Article	IF	CITATIONS
181	Decision Support Needs for Patients with Severe Symptomatic Aortic Stenosis. Journal of Gerontological Social Work, 2021, , 1-15.	1.0	1
182	Health Literacy in Patients Considering a Left Ventricular Assist Device: Findings from the DECIDE-LVAD Trial. Journal of Cardiac Failure, 2022, , .	1.7	1
183	End-Point Selection for Acute Heart Failure Trials. Heart Failure Clinics, 2011, 7, 481-495.	2.1	0
184	Diff'rent Strokes, Different Folks. Circulation: Heart Failure, 2013, 6, 355-357.	3.9	0
185	Predicting in-hospital worsening heart failure at time of admission, but do we really need another heart failure risk model?. American Heart Journal, 2016, 178, 188-189.	2.7	0
186	Gradual Increases in Scheduled and Actual Early Follow-Up After Heart Failure Hospitalization. Circulation: Heart Failure, 2016, 9, .	3.9	0
187	Patient-centered outcomes with next-generation left ventricular assist devices: One small step, not a giant leap. Journal of Heart and Lung Transplantation, 2018, 37, 136-138.	0.6	0
188	Decision Making and Palliative Care in Advanced Heart Failure. , 2020, , 705-718.e3.		0
189	Candidate Selection and Decision Making in Mechanical Circulatory Support. , 2020, , 31-39.		0
190	Process Improvement in Heart Failure. Heart Failure Clinics, 2020, 16, xvii-xix.	2.1	0
191	Mis-GUIDEDâ€"The Importance of Negative Trials of Health Care Delivery and Implementation Science. JAMA Cardiology, 2021, 6, 135.	6.1	0
192	Adding a Rock to a Hard Place. JACC: CardioOncology, 2021, 3, 316-318.	4.0	0
193	Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines – heart failure participating centers. American Heart Journal, 2022, 246, 1-11.	2.7	0